BIOGEN INC. (BIIB)
BIOGEN INC. (BIIB) from its SEC filings: 2025 revenue $9.9 billion (+2% vs the year before), net margin 13%, free cash flow $2.1 billion. Insider trades, recent filings and a price chart. Free.
| Exchange | Nasdaq |
| Industry | Biological Products, (No Diagnostic Substances) |
| Revenue (2025) | $9.9 billion |
| Revenue growth | +2% |
| Net income | $1.3 billion |
| Net margin | 13.1% |
| Free cash flow | $2.1 billion |
| Diluted EPS | $8.79 |
| Latest quarter (Q1 2026 (calendar)) revenue vs a year earlier | +2% |
| Cash | $2.9 billion |
| Long-term debt | $6.3 billion |
| Share count, 1 year | +1% |
| Fundamentals check | Mixed fundamentals |
Source: SEC EDGAR company filings (XBRL), updated 2026-10-23. Education only, not financial advice.